chr11-64593747-G-A
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 16P and 1B. PVS1PP5_Very_StrongBS1_Supporting
The NM_144585.4(SLC22A12):c.774G>A(p.Trp258*) variant causes a stop gained change. The variant allele was found at a frequency of 0.000382 in 1,613,338 control chromosomes in the GnomAD database, including 7 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_144585.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000177 AC: 27AN: 152218Hom.: 1 Cov.: 34
GnomAD3 exomes AF: 0.000283 AC: 71AN: 250516Hom.: 1 AF XY: 0.000192 AC XY: 26AN XY: 135540
GnomAD4 exome AF: 0.000403 AC: 589AN: 1461002Hom.: 6 Cov.: 33 AF XY: 0.000380 AC XY: 276AN XY: 726824
GnomAD4 genome AF: 0.000177 AC: 27AN: 152336Hom.: 1 Cov.: 34 AF XY: 0.000148 AC XY: 11AN XY: 74486
ClinVar
Submissions by phenotype
Dalmatian hypouricemia Pathogenic:6
- -
- -
- -
The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.026%). Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000003512 / PMID: 12024214). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. -
The SLC22A12 c.774G>A (p.Trp258Ter) variant is a stop gained variant predicted to result in premature termination of the protein. The p.Trp258Ter variant is widely reported in the literature as the most common variant associated with renal hypouricemia in Japanese patients, and one of the most common variants in Korean renal hypouricemia patients. Across a selection of the available literature, the p.Trp258Ter variant has been reported in 79 of 91 Japanese and Korean patients, including in 42 individuals in a homozygous state, 24 individuals in a compound heterozygous state, and 13 individuals in a heterozygous state in whom a second variant was not detected (Enomoto et al. 2002; Tanaka et al. 2003; Komoda et al. 2004; Cheong et al. 2005; Komatsuda et al. 2006; Ichida et al. 2008). In a study of 909 subjects from the general Korean population, the p.Trp258Ter variant was observed in one compound heterozygote and 19 heterozygotes, seven of whom had hypouricemia, while a study of 5023 subjects from the general Japanese population reported the p.Trp258Ter variant in five homozygotes, all of whom had hypouricemia, and 225 heterozygotes (Lee et al. 2008; Hamajima et al. 2011). The variant was absent from 424 healthy controls in the above studies but is reported at a frequency of 0.02404 in the Japanese in Tokyo, Japan population of the 1000 Genome Project. This allele frequency is high but is consistent with the disease prevalence. Due to the potential impact of stop-gained variants and the supporting evidence from the literature, the p.Trp258Ter variant is classified as pathogenic for renal hypouricemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
- -
SLC22A12-related disorder Pathogenic:1
The SLC22A12 c.774G>A variant is predicted to result in premature protein termination (p.Trp258*). This variant is considered one of the most common variants associated with renal hypouricemia in individuals of Japanese and Korean descent (Taniguchi et al. 2005. PubMed ID: 16059895; Cheong et al. 2005. PubMed ID: 15912381). Functional studies showed defects in cellular localization and urate transport activity (Enomoto et al. 2002. PubMed ID: 12024214). This variant is reported in 0.36% of alleles in individuals of East Asian descent in gnomAD. Nonsense variants in SLC22A12 are expected to be pathogenic. This variant is interpreted as likely pathogenic. -
not provided Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 3512). This premature translational stop signal has been observed in individuals with renal hypouricemia (PMID: 19092327, 22257548, 23525542, 23652934). This variant is present in population databases (rs121907892, gnomAD 0.3%). This sequence change creates a premature translational stop signal (p.Trp258*) in the SLC22A12 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC22A12 are known to be pathogenic (PMID: 14694169). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at